申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US05045541A1
公开(公告)日:1991-09-03
Fused pyridazine compounds ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and respectively hydrogen, a halogen, hydroxy, nitro, amino, cyano, trifluoromethyl, and alkyl, an alkoxy or an alkanoylamino; one of R.sub.a and R.sub.b is a group of the formula --O--Y--NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are the same or different and respectively hydrogen, an alkyl, a phenylalkyl or a substituted phenylalkyl or a group forming a heterocycle together with the adjacent nitrogen atom and Y stands for a straight- or branched-chain alkylene which may have hydroxy group as a substituent on the chain, and the other is hydrogen, or both of R.sub.a and R.sub.b are the same or different and respectively a group of the formula --O--Y--NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are of the same meanings as defined above; W is .dbd.CH-- or .dbd.N; X is CH.sub.2, S, SO, SO.sub.2 or O; and the bond designated by a broken line in its part stands for a single bond or a double bond, or their pharmaceutically acceptable salts or hydrates and their pharmaceutical use. Said compounds possess stimulating effects on phagocytosis of leukocytes and macrophages, restorative effects on leukopenia, protective effects against infection, antitumor actions and the like and thus they are useable for the prophylaxis or therapy of human diseases accompanied by immunodeficiency.
融合吡嗪化合物 ##STR1## 其中R.sup.1, R.sup.2, R.sup.3 和 R.sup.4 相同或不同,分别代表氢、卤素、羟基、硝基、氨基、氰基、三氟甲基、烷基、烷氧基或烷酰氨基;R.sub.a 和 R.sub.b 中之一为 --O--Y--NR.sup.5 R.sup.6 形式的基团,其中 R.sup.5 和 R.sup.6 相同或不同,分别代表氢、烷基、苯基烷基或取代的苯基烷基,或与相邻氮原子一起形成杂环的基团,Y 代表直链或支链的亚烷基,链上可带有羟基作为取代基,另一者为氢,或者 R.sub.a 和 R.sub.b 两者相同或不同,分别代表上述含义的 --O--Y--NR.sup.5 R.sup.6 形式的基团;W 为 .dbd.CH-- 或 .dbd.N;X 为 CH.sub.2, S, SO, SO.sub.2 或 O;破折号表示的键部分代表单键或双键,或其药学上可接受的盐或水合物及其医药用途。这些化合物具有刺激白细胞和巨噬细胞吞噬作用、恢复白细胞减少、抗感染保护作用、抗肿瘤作用等,因此可用于预防或治疗伴随免疫缺陷的人类疾病。